1185995-26-9
1185995-26-9
Chemical Structure
(±)-Lisofylline-d6
- CAS No.: 1185995-26-9
- Formula:C13H14D6N4O3
- Molecular Weight:286.36
IUPAC Name: 1-(5-hydroxyhexyl)-3,7-bis(methyl-d3)-3,7-dihydro-1H-purine-2,6-dione
InChIKey: NSMXQKNUPPXBRG-XERRXZQWSA-N
SMILES: O=C1C2=C(N(C([2H])([2H])[2H])C(=O)N1CCCCC(C)O)N=CN2C([2H])([2H])[2H]
Biological Activity: (±)-Lisofylline-d6 is the deuterium labeled (±)-Lisofylline[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(±)-Lisofylline-d6 | (±)-Lisofylline-d6 is the deuterium labeled (±)-Lisofylline. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline (Standard) | ≥98% | (±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline-d4 | (±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Lisofylline | 98.57% | (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
